Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating dupilumab for moderate-to-severe atopic hand and foot dermatitis has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis
• Atopic Foot Dermatitis
• Atopic Hand Dermatitis

Drugs mentioned

• Dupilumab (dupilumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Moderate to Severe Atopic Hand and Foot Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2023-12-22